Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality

Recruiting Observational Study
Intraventricular Hemorrhage Pulmonary Hemorrhage Death ELGAN (22-28SA) Bronchopulmonary Dysplasia (BPD) Shock Extracellular Vesicles Enterocolitis, Necrotizing
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 Days – 3 Months
Sex
Any
Study type
Observational
Participants needed
30 (estimated)
Sponsor
University Hospital, Montpellier · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study aims to understand the role of extracellular vesicles (EVs) in extremely premature infants, those born before 28 weeks of gestation. EVs are tiny particles released by cells that carry important information about the body's condition. In extremely premature infants, blood vessels may not function properly, leading to serious health problems such as bleeding in the brain, lung injury, or…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Mother over 18 years old, able to speak and understand French * Newborn less than 28 weeks of gestation, born and hospitalized at Montpellier University Hospital * Umbilical cord venous blood collected immediately after birth (from the segment between the cord clamp and the pl…
Contacts

No contact information available.